Galderma's CEO Flemming Ørnskov revealed that the rising use of GLP-1 weight-loss medications like Ozempic and Wegovy is driving strong growth in the company's aesthetics portfolio, including fillers and anti-wrinkle treatments. About 10% of U.S. adults now use these drugs, creating demand for products that address facial sagging linked to significant weight loss, a condition sometimes called "Ozempic face." Galderma reported nearly 25% sales growth year-on-year at constant currencies, with U.S. sales growing 32%, outpacing other regions. This trend presents a significant but early-stage opportunity for the company in the aesthetics market.
DLocal Ltd. reported a 28.6% year-over-year increase in gross profit for Q2 2026, supported by its API that enables merchants to access local payment methods in over 60 markets. This growth occurred despite pressure on take-rates due to volume discou...
NVIDIA, Apple, and Microsoft now account for over 21% of the S&P 500 index, marking the highest three-stock concentration in its history, surpassing the 1980s peak of 13.4%. This concentration reflects strong earnings and growth, especially driven by...
Palantir Technologies shows faster revenue growth and profitability compared to Snowflake, making it a more attractive long-term AI data stock for retirement investors. Palantir's Q2 revenue surged 92.8% year-over-year, with strong U.S. commercial gr...
West Pharmaceutical Services is recommended as a buy despite its high valuation, supported by strong financial performance and new growth drivers. Key growth factors include double-digit expansion from GLP-1 products, upgrades related to High-Value P...
Noble Mineral Exploration is preparing a 2,500 to 3,000 meter drill program at its Lucas Gold Project near Timmins, Ontario, supported by a $215,000 grant from the Ontario government. The project is drill-ready with established infrastructure and a F...
